A phase IV study has shown that treatment with desmopressin acetate decreases the risk of bleeding after a percutaneous kidney biopsy and reduces hematoma size. "To our knowledge, this is the first randomized controlled trial that shows the efficacy of desmopressin in percutaneous kidney biopsy to decrease bleeding complications in patients without coagulation disorders," says investigator Carlo Manno.Desmopressin is a synthetic derivative of vasopressin that exerts its hemostatic effects by increasing levels of von Willebrand factor and factor VIII. To evaluate the efficacy of desmopressin, 162 patients with recurrent macrohematuria and/or urinary abnormalities or nephrotic syndrome were randomly assigned to receive desmopressin (n = 80) or to receive placebo (n = 82) 1 h before a native kidney biopsy. Baseline characteristics were similar in the two groups.
展开▼
